Pharmaceutical composition for preventing or treating cancer, comprising an inhibitor of CD300c expression or activity
A pharmaceutical composition targeting CD300c protein on cancer cells enhances T cell activity and suppresses cancer proliferation, addressing the limitations of current treatments by providing a broad-spectrum immuno-anticancer solution.
Patent Information
- Application Number
- JP2023034155
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-24
- Filing Date
- 2023-03-07
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-05-27
AI Technical Summary
Current cancer treatments, including cytotoxic and targeted anticancer drugs, suffer from significant side effects and resistance issues, while immune checkpoint inhibitors are not effective across various cancer types, necessitating the development of new immuno-anticancer drugs that target specific proteins on cancer cells to enhance T cell activity and suppress cancer cell proliferation.
A pharmaceutical composition containing a CD300c expression or activity inhibitor, such as antisense oligonucleotides, short hairpin RNA, ribozymes, antibodies, or peptides, is used to suppress the CD300c protein on cancer cells, thereby enhancing T cell activity and inhibiting cancer cell proliferation.
The CD300c inhibitor increases T cell activity, reduces cancer cell proliferation, and suppresses tumor growth by inhibiting myeloid-derived suppressor cells, offering a new immunotherapeutic approach effective against various cancers, including colorectal, lung, and breast cancers.
Smart Images

Figure 0007577252000001 
Figure 0007577252000002 
Figure 0007577252000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition comprising an inhibitor of the expression or activity of CD300c protein. etc. [Background technology]
[0002] Cancer is one of the most common causes of death in modern society, and various It is a disease caused by a genetic mutation that occurs due to various reasons, resulting in a change in normal cells. It refers to a malignant tumor that does not follow the differentiation, proliferation, and growth patterns of normal cells. is characterized as "uncontrolled cell growth," and such abnormal cell growth can lead to tumors. These cells form masses called cytoplasmic cells, which can infiltrate the surrounding tissue and, in severe cases, damage other organs in the body. Even if cancer is treated with surgery, radiation, and drug therapy, it often It is an intractable chronic disease that does not provide a fundamental cure, causes pain to the patient, and ultimately leads to death. It is a disease.
[0003] Cancer drug therapy, i.e., anticancer drugs, are generally compounds that have cytotoxicity and act to destroy cancer cells. It treats cancer by attacking and destroying cancer cells, but it also damages normal cells as well as cancer cells. Therefore, targeted anticancer drugs have been developed to reduce side effects. However, in the case of such targeted anticancer drugs, side effects can be reduced. However, a limit was reached where resistance is highly likely to occur (Korean Patent Publication 10-2018-00 Therefore, more recently, the immune system of the body has been used to treat problems caused by toxicity and resistance. There is a growing interest in immunotherapy for cancer. As an example of a cancer drug, it binds to PD-L1 on the surface of cancer cells and inhibits the binding of T cells to PD-1. An immune checkpoint inhibitor has been developed that activates T cells and attacks cancer cells. However, even with these immune checkpoint inhibitors, the types of cancer in which they are effective are limited. A new immune checkpoint that shows the same therapeutic effect in various cancers because the immune checkpoints are not diverse The current situation is that there is a need to develop inhibitors.
[0004] Therefore, the present inventors have demonstrated that PD-L1-like expression on the surface of cancer cells in various cancers As a result of intensive research into proteins that suppress the expression of T cells, the present invention was completed. . Summary of the Invention [Problem to be solved by the invention]
[0005] The present invention has been devised to solve the above-mentioned problems in the prior art. suppresses the expression or activity of CD300c protein present on the surface of various cancer cells By doing so, it was confirmed that T cell activity could be increased and the proliferation of cancer cells could be suppressed, and CD A pharmaceutical for preventing or treating cancer, comprising an expression inhibitor or activity inhibitor of 300c as an active ingredient The present invention aims to provide a composition having a desired effect.
[0006] However, the technical problem that the present invention aims to achieve is not limited to the problems mentioned above. Other problems not mentioned above and not mentioned will be understood by those of ordinary skill in the art from the following description. can be clearly understood by those [Means for solving the problem]
[0007] The present invention relates to a method for preventing cancer, comprising the step of administering to a subject a drug that inhibits the expression or activity of CD300c as an active ingredient. or a therapeutic pharmaceutical composition.
[0008] In one embodiment of the present invention, the CD300c expression inhibitor is preferably an inhibitor of CD30 antisense oligonucleotide (ASO) that binds complementary to the mRNA of the 0c gene; Short hairpin RNA, small interfering RNA (siRNA), ribozymes, etc., and the CD300c gene There is no limitation thereto, so long as the substance reduces or inhibits the expression of a CD3 gene. The mechanism by which the expression of 00c is suppressed is not particularly limited, and examples thereof include inhibition of gene expression such as transcription and translation. This can act as a mechanism to suppress the onset of
[0009] In another embodiment of the present invention, the agent for suppressing CD300c activity is Compounds that bind to complementary proteins, peptides, peptidomimetics, substrate analogs, aptamers, etc. markers, antibodies, etc., which bind to the CD300c protein and reduce or inhibit the activity of CD300c. The substance is not limited thereto as long as it inhibits the activity of the CD300c protein. The mechanism of inhibition is not particularly limited, and an example of the mechanism of inhibition is the conversion of an active form to an inactive form. An example of the antibody may be a polyclonal antibody. , may be a monoclonal antibody, preferably a human monoclonal anti-CD300c The antibody may be an antibody or an antibody fragment, but it is capable of specifically binding to CD300c. The soluble receptor is not limited to an antibody that binds to CD300c. The receptor preferably comprises a sequence that specifically binds to the amino acid sequence of SEQ ID NO:1. However, the present invention is not limited thereto, so long as it is a receptor that binds to CD300c.
[0010] In yet another embodiment of the present invention, the cancer is preferably colorectal cancer, rectal cancer, colon cancer. , thyroid cancer, oral cancer, pharyngeal cancer, laryngeal cancer, cervical cancer, brain cancer, lung cancer, ovarian cancer, bladder cancer, kidney cancer , liver cancer, pancreatic cancer, prostate cancer, skin cancer, tongue cancer, breast cancer, uterine cancer, stomach cancer, bone cancer, blood cancer, etc. Any type of cancer that expresses CD300c protein on the surface of cancer cells may be used, including but not limited to this. stomach.
[0011] In yet another embodiment of the present invention, the pharmaceutical composition further comprises other conventional anti-cancer agents. The anticancer drug may preferably be doxorubicin, cisplatin, gemcitabine, or the like. bin, oxaliplatin, 5-FU, cetuximab, panitumumab, nimotuzumab, neci Tumor antigens, anti-cancer viruses, and other substances currently used as anti-cancer drugs are The cancer antigen is a cancer vaccine specific to a carcinoma, preferably a bladder cancer vaccine. NY-ESO-1 is a bladder cancer specific cancer antigen, HER2 is a breast cancer specific cancer antigen, and The specific cancer antigens were CEA, and the specific cancer antigens for lung cancer were VEGFR1 and VEGFR2. However, the present invention is not limited to this, as long as the type of cancer antigen is known as a cancer vaccine. Examples of anti-cancer viruses include Imligic and Pexavec. The present invention is not limited to this, so long as the anticancer agent is an anticancer drug. The anti-cancer drug may be administered or may be in a form bound to the inhibitor of the present invention, and may be administered in a delivery system for the anti-cancer drug. The above-mentioned configuration may be such that the above-mentioned configuration is included together with the above-mentioned configuration.
[0012] In yet another embodiment of the invention, the pharmaceutical composition is for use in treating cancer or cancer stem cell proliferation, The pharmaceutical composition of the present invention is characterized by suppressing survival, metastasis, recurrence, and resistance to anticancer drugs. The effect is not limited to this, as long as it is generated by
[0013] The present invention also relates to a method for treating a cancer cell line comprising the steps of: (a) culturing a cancer cell expressing a CD300c protein; (b) treating the cultured cancer cells with a candidate substance; and (c) detecting the candidate substance. (d) measuring the expression level of CD300c in the cells treated with the and selecting a candidate substance that reduces the expression level. A method for selecting the above is provided.
[0014] The present invention also relates to a method for treating a CD300c protein with a candidate substance; b) screening candidate substances bound to the CD300c protein; A method for screening a substance for preventing or treating cancer is provided.
[0015] In one embodiment of the present invention, the step of measuring the expression level includes measuring the expression level of mRNA and / or or measuring the expression level of a protein, and not measuring the expression level of mRNA. by determining the presence and expression level of CD300c mRNA in biological samples. This can be confirmed by measuring the amount of mRNA. The methods include RT-PCR and competitive RT-PCR. R), real-time RT-PCR, RNase protection assay (RPA), These include, but are not limited to, immunoblotting and DNA microarray chips. Furthermore, measuring the expression level of the protein does not necessarily mean that CD30 is isolated from a biological sample. determining the presence or absence and expression level of the CD300c protein, The amount of protein can be confirmed by using an antibody that specifically binds to the protein. The activity of the enzyme can be measured by the analysis of the protein. Stan blotting, ELISA (enzyme-linked immunosorbent assay), radioimmunoassay Say, radial immunodiffusion, Ouchterlony Ouchterlony immunodiffusion, Rocket immunoelectrophoresis, immunohistochemistry These include histochemical staining, immunoprecipitation analysis, complement fixation analysis, FACS, and protein chips. However, the present invention is not limited to these.
[0016] In another embodiment of the present invention, the step of selecting a substance that binds to the candidate substance comprises the steps of: A method for selecting a substance that binds to D300c protein, comprising the steps of: For this purpose, Western blotting, ELISA (enzyme-linked immunosorbent assay), and radioimmunoassay are used. Immunoassay, radial immunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, Immunohistochemical staining, immunoprecipitation analysis, complement fixation analysis, FACS, protein chips, etc. However, the present invention is not limited to these.
[0017] In yet another embodiment of the invention, the candidate substance is a nucleotide, DNA, RNA , amino acids, aptamers, proteins, compounds, natural products, natural extracts, vectors, etc. is not restricted by this.
[0018] The present invention also relates to a drug comprising an inhibitor of CD300c expression or activity as an active ingredient. The present invention provides a method for treating cancer comprising administering to an individual a therapeutic composition comprising:
[0019] The present invention also relates to a drug comprising an inhibitor of CD300c expression or activity as an active ingredient. The present invention provides a method for the prevention or treatment of cancer using a pharmaceutical composition. Effect of the Invention
[0020] The expression or activity inhibitor of CD300c according to the present invention is a compound that inhibits the expression of CD300c on the surface of various cancers. It activates T cells by binding to CD300c and suppressing the expression of CD300c. It is expected to be used as an immunotherapeutic agent for various cancers by activating the immune system and suppressing the proliferation of cancer cells. Such inhibitors can be effectively used to inhibit tumor-infiltrating lymphocytes and cells in the cancer environment. It increases the number of toxic T lymphocytes and decreases the number of myeloid-derived suppressor cells, and also suppresses the growth and development of cancer. Since the expression or activity inhibitor of CD300c of the present invention can effectively suppress the expression and development of CD300c, It is expected that the agent can be effectively used as a new immunotherapeutic agent in the treatment of cancer. [Brief description of the drawings]
[0021] [Figure 1] FIG. 1 shows the results of SDS-PAGE of sCD300c-Fc according to one embodiment of the present invention. [Diagram 2] FIG. 2 shows the results of confirming the effect of sCD300c-Fc according to one embodiment of the present invention on tumor-infiltrating lymphocytes. [Diagram 3] FIG. 3 shows the results of confirming the effect of sCD300c-Fc according to one embodiment of the present invention on the signal transduction mechanism of NF-κB. [Figure 4] FIG. 4 shows the results of examining the effect of an anti-CD300c antibody according to one embodiment of the present invention on human T cells. [Diagram 5] FIG. 5 shows the results of confirming the inhibitory effect of an anti-CD300c antibody according to one embodiment of the present invention on the growth of lung cancer. [Figure 6]FIG. 6 shows the results of confirming the inhibitory effect of an anti-CD300c antibody according to one embodiment of the present invention on the growth of breast cancer. [Figure 7] FIG. 7 shows the results of confirming the colon cancer growth inhibitory effect of an anti-CD300c antibody according to one embodiment of the present invention. [Figure 8] FIG. 8 shows the results of confirming the in vivo cancer growth inhibitory effect of the anti-CD300c antibody according to one embodiment of the present invention. [Figure 9] FIG. 9 shows the results of confirming the in vivo cancer growth inhibitory effect of the anti-CD300c antibody according to one embodiment of the present invention. [Figure 10] FIG. 10 shows the results of confirming the cancer growth inhibitory effect of CD300c siRNA according to one embodiment of the present invention. [Figure 11] FIG. 11 shows the results of examining the effect of an anti-CD300c antibody according to one embodiment of the present invention on anti-cancer immune responses. [Figure 12] FIG. 12 is a schematic diagram showing the mechanism by which an anti-cancer effect is exerted by suppressing the function and / or expression of CD300c. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] The expression or activity inhibitor of CD300c of the present invention inhibits tumor-infiltrating lymphocytes in a cancer environment. and increase the number of cytotoxic T lymphocytes and decrease the number of myeloid-derived suppressor cells, It is believed that CD300c-expressing cells can effectively suppress the growth and development of various cancers. These compounds can be effectively used to treat a variety of cancers.
[0023] As used herein, the term "antibody" refers to an immunoglobulin that is immunologically reactive with a specific antigen. The antibody includes polyclonal antibodies, monoclonal antibodies and functional fragments thereof. The term also includes chimeric antibodies (e.g., human anti-mouse antibodies) and heterologous conjugate antibodies. (e.g., bispecific antibodies) Among these, monoclonal antibodies are highly specific to a single antigenic site (epitope). A polyclonal antibody is an antibody that is specific to a specific epitope and contains different antibodies against different epitopes. In contrast, monoclonal antibodies respond to only a single epitope on an antigen and therefore are The antibody is a polymer that is easy to control for quality control as an antibody. and / or light chain variable regions, the variable regions having a primary structure that corresponds to the antigen of an antibody molecule. The antibody of the present invention is composed of a fragment containing the variable region. Preferably, the variable region can be substituted for a soluble receptor for CD300c. However, the present invention is not limited thereto, so long as it exhibits the same effect as the anti-CD300c antibody of the present invention.
[0024] As used herein, "prevention" refers to the prevention of a disease such as cancer by administration of the pharmaceutical composition according to the present invention. It refers to any action that inhibits or delays the onset of disease.
[0025] As used herein, "treatment" refers to the treatment of a disease such as cancer by administration of a pharmaceutical composition according to the present invention. It means any action that improves or changes the situation to one's advantage.
[0026] As used herein, the term "individual" refers to a subject to which the pharmaceutical composition of the present invention can be administered. There are no restrictions on the subject.
[0027] As used herein, the term "pharmaceutical composition" refers to a capsule, tablet, granule, injection, ointment, or the like. The pharmaceutical composition is in the form of a powder or drink, and is intended for humans. The pharmaceutical composition includes, but is not limited to, Oral dosage forms such as powders, granules, capsules, tablets, and aqueous suspensions, and topical preparations can be prepared by conventional methods. The pharmaceutical composition of the present invention can be used in the form of a suppository or a sterile injection solution. The composition may contain a pharma- ceutically acceptable carrier. The pharma- ceutically acceptable carrier is, when administered orally, These include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, and pigments. In the case of injections, buffering agents, preservatives, pain relievers, solubilizers, etc. can be used. In the case of topical administration, a base agent, an isotonic agent, a stabilizer, etc. can be mixed and used. , excipients, lubricants, preservatives, etc. may be used. The dosage form of the pharmaceutical composition of the present invention may be It can be prepared in various ways by mixing with the pharma- ceutically acceptable carriers as described above. For example, oral administration For administration, it may be administered as a tablet, troche, capsule, elixir, or suspension. It can be manufactured in the form of tablets, syrup, wafers, etc., and in the case of injections, it can be manufactured in the form of unit doses. They can be manufactured in single or multi-dose forms. Other options include solutions, suspensions, tablets, capsules, etc. It can be formulated as a cell, sustained release formulation, etc.
[0028] On the other hand, examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, and the like. Lose, sucrose, sorbitol, mannitol, xylitol, erythritol, malate Lutitol, starch, gum acacia, alginate, gelatin, calcium phosphate , calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl chloride Nylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate , talc, magnesium stearate or mineral oil may be used. It may further comprise flocculating agents, lubricants, wetting agents, flavorings, emulsifiers, preservatives, and the like.
[0029] The administration route of the pharmaceutical composition according to the present invention includes, but is not limited to, oral, Intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, percutaneous, subcutaneous, intraperitoneal, intranasal, intestinal Oral or parenteral administration is preferred. The term "parenteral" includes any of the following: subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intraperitoneal ... The pharmaceutical compositions of the present invention may also be administered orally, intralesionally, or intracranially. It may be administered in the form of suppositories for rectal administration.
[0030] The pharmaceutical compositions of the present invention may be prepared in a variety of ways, depending on the activity of the particular compound used, age, weight, general health, Gender, diet, time of administration, route of administration, excretion rate, drug combination and specific disease being prevented or treated The dosage of the pharmaceutical composition may vary depending on various factors, including the severity of the disease, and may be adjusted according to the patient's condition. The dosage will vary depending on the patient's condition, weight, severity of the disease, drug form, route of administration and duration, but it is within the skill of the art to The dose may be more appropriately selected from 0.0001 to 500 mg / kg or 0.001 to 50 The dosage can be once a day or several times a day. The dosage amounts do not limit the scope of the invention in any way. The pharmaceutical composition according to the present invention may be in the form of a pill, dragee, capsule, liquid, gel, etc. The composition may be formulated as a syrup, a slurry or a suspension.
[0031] The following examples are presented below to aid in the understanding of the present invention. The examples are provided merely so that the invention may be more readily understood. The contents of the present invention are not limited thereto. EXAMPLES
[0032] [Example 1: Preparation of sCD300c-Fc] To analyze the function of CD300c in cancer cells and the immune system, we used antibodies against soluble CD300c. The Fc portion of the heavy chain region of the sCD300 was bound to sCD300c-Fc. To prepare 0c-Fc, a gene encoding the amino acid sequence of SEQ ID NO:3 (SEQ ID NO:4) was used. ) was inserted into pcDNA3.1, which was then transformed into the HEK293T cell line. Transformed cells for the production of sCD300c-Fc, and intracellular gene delivery The polymer, which increases the efficiency, was added to RPM supplemented with fetal bovine serum with a very low IgG content. I medium and cultured in a cell culture vessel for 4 days. After the culture was completed, the centrifuge was The supernatant containing sCD300c-Fc was separated using a 0.22 μm filter. The mixture was filtered once through a recombinant protein A Sepharose column (GE Heal) sCD300c-Fc was isolated and purified using Thcare, and purified sCD3 The absorbance of sCD300c-Fc was measured to determine the concentration. Fc 2μg was added to Reducing sample buffer and Non-reducing After adding pre-made SDS-PAGE to the reducing sample buffer, The gel was electrophoresed using 100-PAGE gel (Invitrogen). The proteins were stained with Chromatin Blue and the results are shown in Figure 1.
[0033] As shown in Figure 1, it was confirmed that sCD300c-Fc with a purity of 90% or higher was purified. I acknowledged.
[0034] [Example 2: Confirmation of the effect of sCD300c-Fc on tumor-infiltrating lymphocytes] sCD300c-Fc inhibits tumor infiltrating lymphocytes To confirm the effect on TIL, the same method as in Example 1 was used. The experiment was carried out using sCD300c-Fc prepared in the above. The cells were cultured in endothelial cells in EBM medium (endothelial endothelial cell membrane) supplemented with 1% fetal bovine serum (FBS). l basal medium, Lonza) was dispensed and 1 × 10 6 Cells / mL of human blood endothelial cells (human umbilical vein endothelial cells; HUVEC, PromoCell) and 1 × 10 5 Thin Peripheral blood mononuclear cells (PBMCs, CTLs) were inoculated at 10 cells / mL and sCD300c-Fc was administered at 10 The cells were treated with the following concentrations: 1, 0.1, 0.01, and 0.001 nM. Then, the cells were incubated at 37°C for 5 After incubation for 16 hours under 5% CO2, the absorbance at OD450nm was measured to determine tumor infiltration. The number of infiltrating lymphocytes was measured, and the results are shown in Figure 2.
[0035] As shown in Figure 2, the increased concentration of sCD300c-Fc increased the number of tumor-infiltrating lymphocytes. We confirmed that the number of sCD300c-Fc-dependent markers increased, and that this increased the number of sCD300c-Fc-dependent markers ... in the peripheral blood. Blood mononuclear cells differentiate into lymphocytes that infiltrate into human vascular endothelial cells, and the number of lymphocytes increases. It was confirmed that the number of cells increased depending on the concentration of sCD300c-Fc used. The results confirmed that immune cells can be activated through the processing of sCD300c-Fc. I was able to do it.
[0036] [Example 3: Confirmation of the effect of sCD300c-Fc on the NF-κB signaling mechanism] To confirm the effect of sCD300c-Fc on NF-κB signaling, The experiment was carried out using sCD300c-Fc prepared in the same manner as in Example 1. THP-1 blue cells (monocyte cells, Invivogen) were cultured in a 96-well plate. After seeding at 5,000 cells per well, the cells were cultured for 12 hours. The sCD300c-Fc, LPS (lipopolysaccharide) and After treatment of each well with IgG and / or IgG, the wells were incubated at 37°C, 5% CO2 for 48 hours. The culture supernatant was then separated and incubated for 1 h. The supernatant was then incubated for 1 h. The supernatant was then incubated for 1 h. n) was treated and reacted for 1 hour, and the absorbance was measured at 650 nm to determine the NF-κB The signal intensity was measured, and the results are shown in Figure 3.
[0037] As shown in Figure 3, in the control group treated with LPS alone, the NF-κB signal was 0. The control group treated with sCD300c-Fc showed a baseline value of approximately 0.8. On the other hand, in the experimental group treated with both LPS and sCD300c-Fc, We confirmed that NF-κB signaling was significantly increased by heat inactivation. sCD300c-Fc(hisCD300c-Fc; heat inactivat ed sCD300c-Fc) did not affect NF-κB signaling. These results confirmed that sCD300c-Fc mediates the signal transduction mechanism of NF-κB. This activates the immune cells, THP-1 monocytes, and promotes their differentiation into macrophages. It was confirmed that the innate immune system can be efficiently activated by promoting the expression of the IL-1 receptor agonist, IL-1, in the innate immune system.
[0038] [Example 4: Preparation of anti-CD300c antibody] (4.1. Generation of anti-CD300c polyclonal antibody) CD30 used as antigen to generate polyclonal antibodies against CD300c The gene for the extracellular domain of 0c (SEQ ID NO: 2) was transformed into pE The resulting vector was inserted into the T28a (Novagen) expression vector and transformed into E. coli. The transformed E. coli was cultured in 100 mL of LB supplemented with 100 mg / mL ampicillin. After inoculating the medium, the absorbance is measured at OD 600nm Incubate the mixture at 0.8 to 1.0 with I PTG was added, and the cells were incubated at 25°C for 16 hours to detect His-tagged CD30 After inducing the expression of 0c, the culture medium was centrifuged to remove the supernatant, and the cells were harvested. The cells were cultured in 50 mM NaH2PO4 and 500 mM NaCl (pH 8.0). The cells were resuspended in a solution containing 100% ethanol and disrupted by ultrasonication. Cell lysates were obtained for use in protein purification through a centrifugation and filtration process. His-tagged CD300c (SEQ ID NO: 5; CD300 c-His) is a Ni-NTA Sepharose column (GE healt The affinity chromatography method using hcare was used. His-tagged CD3 was purified by step gradient elution. The purified His-tagged CD300c was eluted in the same manner as in Example 1. SDS-PAGE was performed using the method described above, and CD300c with His-tags of 90% or higher purity was obtained. It was confirmed that it was manufactured.
[0039] The purified His-tagged CD300c was then used to More specifically, purified His-tagged CD300c antibody was used to immunize mice. The original solution was diluted with phosphate buffered saline (PBS) to a concentration of 0.5 mg / 400 μL, and the same amount of The primary immunization was performed by subcutaneous injection of the mixture with complete Freund's adjuvant (Sigma). Two weeks later, the mice were treated with 0.5 mg / 400 μL of antigen and the same amount of incomplete Freund's adjuvant. Secondary immunization was performed in the same manner using a mixture of bunt (Sigma), and then the mice were immunized in the same manner at 2-week intervals. After the third immunization, blood was collected from the tail vein and then used for the fourth and final immunization. The collected blood was diluted 1 / 1,000 and ELISA was performed to evaluate the antibody activity. After the final fourth immunization, whole blood was collected from the rabbits after anesthesia to obtain plasma.
[0040] (4.2. Confirmation of antibody specificity of anti-CD300c antibody) In order to confirm the specificity of the anti-CD300c antibody produced in the same manner as in Example 4.1, CD30 diluted at concentrations of 1ng, 10ng, 100ng, 500ng, and 1μg The specificity for the 0c antigen was evaluated by ELISA and Western blotting was performed. As a result, anti-CD300c antibody was found to be CD300c anti It was confirmed that it reacts specifically with the genotype.
[0041] 4.3. Purification of Anti-CD300c Antibody To purify anti-CD300c antibodies from plasma obtained in the same manner as in Example 4.1 The affinity purification method was used. 00c antigen and NHS activated sepharose Fast Flow Resin (GE Healthcare) was dissolved in coupling buffer (0.2 The affinity column was mixed with 0.5 M NaHCO3 and 0.5 M NaCl, pH 8.3. A gel was prepared and packed in a polypropylene column. The obtained plasma was added to the column, and only the antibodies that specifically bind to the antigen were left on the column. .1M glycine (pH 2.5) and 0.1M citric acid (pH 3.0) were mixed The antibody was purified using elution buffer, and the purified antibody was eluted using phosphate buffer. After dialysis, the solution was concentrated and dispensed at a concentration of 1.0 mg / mL. The solution was stored at -80°C. It was kept until now.
[0042] (Example 5: Confirmation of the effect of anti-CD300c antibody on T cells) We conducted experiments to confirm the effect of anti-CD300c antibodies on human T cells. Alternatively, T cell isolation kit (130- 096-534, Milltenyi) to obtain pan T cells The isolated T cells were then plated in a 96-well plate at 5,000 cells per well. After inoculation into cells, the cells were cultured for 6 hours to stabilize them, and then anti-CD3 antibody (B The cells were treated with anti-CD28 antibody (Biolegend) and anti-CD28 antibody (Biolegend). Anti-CD300c polyclonal antibodies purified in the same manner as in Example 4.3 were treated at different concentrations. After culturing at 37°C for 48 hours, the culture supernatant was separated and the amount of IL-2 was measured. The amount of IL-2 was measured using the IL-2 Quantikine kit (R&D system). The results are shown in Figure 4.
[0043] As shown in FIG. 4, in the experimental group treated with anti-CD300c antibody, Therefore, it was confirmed that the amount of IL-2 increases. In this case, it increases the amount of IL-2 secreted and activates T cells, which are part of the adaptive immune system. I was able to confirm this.
[0044] [Example 6: Confirmation of anti-cancer effect of anti-CD300c antibody in vitro] (6.1. Confirmation of the effect of anti-CD300c antibody in suppressing lung cancer growth) To confirm whether anti-CD300c antibody has the effect of suppressing the growth of lung cancer, We confirmed whether A549 cells have the CD300c antigen on their surface. A549 cancer cell line was fixed with 4% formaldehyde and then soaked in 5% normal goat blood. The cells were blocked with supernatant and then treated with 1 μg of anti-CD300c antibody. Afterwards, the cells were stained with FITC-labeled anti-rabbit IgG antibody. The cells were examined using a flow cytometer (FACS). The results are shown in FIG. 5A. did.
[0045] As shown in Figure 5A, human lung cancer cell lines possess the CD300c antigen. Confirmed.
[0046] In addition, to confirm whether the growth of lung cancer is suppressed, the effect of inhibiting the proliferation of cancer cells was examined. More specifically, A549 cells were cultured in a 96-well plate at 10,000 cells per well. After inoculation, the mixture was incubated for 18 hours to stabilize. The cells were treated with 10 μg / mL of anti-CD300c antibody and cultured for 72 hours. The photographs were taken using a mirror. The results are shown in Figure 5B. CK-8 (Dijindo) was added at 10 μL each, and the mixture was reacted for 4 hours. The absorbance was measured at 100 nm, and the results are shown in Figure 5C.
[0047] As shown in Figures 5B and 5C, increasing the treatment concentration of anti-CD300c antibody The results confirmed that the anti-CD300c antibody inhibits the proliferation of lung cancer cells. It was found to inhibit growth.
[0048] (6.2. Confirmation of the effect of anti-CD300c antibody in suppressing breast cancer growth) In order to confirm whether anti-CD300c antibody has an effect of suppressing the growth of breast cancer, Example 6 The same method as in 1 was used to measure the cytostatic effect of breast cancer cell line MDA-MB-231 cells. The results are shown in Figure 6.
[0049] As shown in FIG. 6, the proliferation of breast cancer cells increased with increasing concentration of anti-CD300c antibody. This confirmed that anti-CD300c antibody suppresses breast cancer growth. We were able to confirm this.
[0050] (6.3. Confirmation of the effect of anti-CD300c antibody in suppressing colon cancer growth) To confirm whether anti-CD300c antibody has the effect of suppressing the growth of colon cancer, The same method as in 6.1 was used to measure the cytostatic effect of CT-26 cells, a metastatic colon cancer cell line. The results are shown in Figure 7.
[0051] As shown in FIG. 7, the increase in the concentration of anti-CD300c antibody increased the proliferation of colon cancer cells. It was confirmed that the proliferation of colon cancer cells was suppressed, and thus anti-CD300c antibodies suppress the growth of colon cancer. I was able to confirm that.
[0052] [Example 7: Confirmation of anti-cancer effect of anti-CD300c antibody in vivo] (7.1. Confirmation of the effect of anti-CD300c antibody in inhibiting colon cancer growth) Confirmation of whether anti-CD300c antibody has the effect of suppressing cancer cell growth in vivo To investigate the mechanism of action of the CT-26 cell line, a metastatic colon cancer cell line, in 8-week-old BALB / c mice, we 5×10 5 The mice were subcutaneously injected with IgG4-α / α-cells into the right flank and kept with food and water. Animal care and all experimental procedures were carried out in accordance with the laws and regulations for animal experiments. The tumor size was about 70 mm. 3 When it reaches 0.1, 1, and after intraperitoneal administration of 10 μg of anti-CD300c antibody on days 0, 1, and 5. The tumor size was then confirmed. As a control group, phosphate buffer solution was injected. The results were as follows: Shown in Figure 8.
[0053] As shown in Figure 8, the increase in the concentration of anti-CD300c antibody was associated with a decrease in the size of metastatic colorectal cancer. The increase in tumor size was reduced, and in the experimental group treated with 10 μg, tumor growth was complete by the 15th day. It was confirmed that the tumor was completely suppressed and did not grow any more.
[0054] (7.2. Confirmation of the effect of anti-CD300c antibody in inhibiting lung cancer growth) The same experiment as in Example 7.1 was carried out using an animal model of lung cancer. BALB / c mice were inoculated with 5×10 human lung cancer cell line A549 cells. 6 I'll become a cell The mice were subcutaneously injected into the right flank of the mice and were kept with food and water. The diameter of the tumor was When the cells reached approximately 3–5 mm, anti-CD300c at concentrations of 1, 10, and 100 mg / kg was administered. Antibodies were administered intraperitoneally on days 0, 1, and 5, after which the tumor size was determined. A group was injected with phosphate buffer. The results are shown in FIG.
[0055] As shown in FIG. 9, the proliferation of lung cancer was suppressed as the concentration of anti-CD300c antibody increased. Based on the above results, it was confirmed that the anti-CD300c antibody of the present invention did not cause tumor growth. It was also confirmed that it effectively inhibited cancer growth in vivo.
[0056] These results suggest that anti-CD300c antibodies can effectively inhibit the proliferation of various cancers. It was confirmed that anti-CD300c antibody can be used as an anticancer agent.
[0057] [Example 8: Confirmation of anticancer effect of CD300c siRNA] To further confirm the effect of CD300c on cancer cell proliferation, we We confirmed whether the suppression of CD300c has an anti-cancer effect. Lung cancer according to the manual provided by (sc-93646, SantaCruz) CD300c expression was suppressed in the cell line A549 cells. The siRNA was transfected with Lipofectamine RNAiM. After transfection of cells with 500 μg / ml of ... The cells were then cultured for 1 h. Then, the cultured cells were lysed in a cell lysis solution (20 mM Tris-HCl ( pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1 % Triton, 2.5 mM sodium pyrophosphate, 1 mM glycerophosphate, 1 mM M Na3VO4, 1 μg / mL leupeptin, and 1 mM PMSF). The cell lysate was then collected, and the amount of protein contained in the lysate was determined using the BCA method. The same amount of CD300c-specific binding antibody (PA5-87 Western blotting was performed using a 097 Thermofisher. The results are shown in Figure 10A. To confirm the effect of inhibiting the proliferation of cancer cells, After seeding A549 cells at 10,000 cells per well on a well plate, The cells were then cultured for 18 hours for stabilization. After siRNA treatment, the cells were cultured for 5 days. The absorbance was measured using CCK-8, and the results are shown in Figure 10B.
[0058] As shown in Figure 10A, CD300c siRNA was used to express CD300c in cells. As shown in FIG. 10B, the expression of siR was suppressed in cancer cell lines. It was confirmed that NA treatment suppressed cell proliferation.
[0059] Based on the above results, it was found that suppressing the expression of CD300c exerts an anti-cancer effect. It was confirmed that siRNA (small interfering RNA), antisense oligonucleotides Suppression of CD300c expression using ASO, miRNA, etc. We also investigated the activity of CD300c using antibodies and aptamers that specifically bind to CD300c. It was confirmed that suppressing the activity of GABA receptors can be effective in treating various types of cancer. I was able to acknowledge this.
[0060] [Example 9: Confirmation of anti-cancer immune effect through inhibition of CD300c function and / or expression] By suppressing the function and / or expression of CD300c, it exerts an anti-cancer immune effect. In order to confirm whether the colon cancer cell line was transplanted in the same manner as in Example 7.1, BALB / c mice were used. Mice were intraperitoneally injected with 10 μg of anti-CD300c antibody on days 0, 1, and 5. After euthanasia on the 7th day, the mice were cultured and their bone marrow was isolated. Myeloid- derived suppressor cells MDSCs), lymphocytes, and cytotoxic T lymphocytes were analyzed by flow cytometry (FACS). The results are shown in Figure 11.
[0061] As shown in FIG. 11, in mice treated with anti-CD300c antibody, lymphocytes and In the case of cytotoxic T lymphocytes (CD8+), the number increases, and lymphocytes undergo differentiation induction ( On the other hand, the number of myeloid-derived suppressor cells was reduced. The above results confirmed that the inhibition of the function and / or expression of CD300c Therefore, activation of the immune system was induced in the blood of cancer animal models, leading to activation or increase in T immune cells. By reducing the number of myeloid-derived suppressor cells that suppress proliferation, the anti-cancer immune effect is significantly improved. It was confirmed that the increased expression of β-amyloides in the blood increased the expression of β-amyloides, which is effective in treating cancer.
[0062] Figure 12 shows that the anti-cancer effect is achieved by suppressing the activity and / or expression of CD300c. A simplified diagram of the mechanism by which the present invention is based on previously known immune checkpoints. B7 family members that form tumor CD300c is expressed on the surface of T cells and acts as a binding molecule (Binding Part ner) and suppresses T cell activation, but has a specific function against CD300c. By treating the cells with anti-CD300c antibodies that specifically bind to the CD300c receptor, the activation and proliferation of T cells was stimulated. It exerts an anti-cancer effect by binding to CD300c on the surface of tumor cells and directly inhibits tumor proliferation. This is because the oligonucleotide that suppresses the expression of CD300c suppresses proliferation. The same effect was observed when CD300c expression on the tumor surface was suppressed using an octide. It is confirmed that:
[0063] Therefore, the above results suggest that suppressing the expression and / or function of CD300c and increase the number of tumor-infiltrating lymphocytes and cytotoxic T lymphocytes in the cancer environment, leading to bone marrow transplantation. It reduces the number of marrow-derived suppressor cells, effectively activating the body's anti-cancer immune response, It has been confirmed that it can inhibit cell proliferation and effectively inhibit the growth and development of cancer. Substances that suppress the expression and / or function of CD300c are being developed to treat the proliferation, recurrence, metastasis, etc. of various cancers. It was confirmed that it can be effectively used to suppress
[0064] The above description of the invention is given by way of example only and is not intended to be limiting of the scope of the invention. A person having ordinary skill in the art could easily make the above-mentioned modifications without changing the technical idea or essential features of the present invention. It is understood that other specific forms can be easily modified. The above-described embodiments are illustrative in all respects and are not limiting. It should be understood. [Industrial Applicability]
[0065] The present invention relates to a novel use of CD300c protein present on the surface of various cancer cells. By suppressing the expression or activity of CD300c protein, the activity of T cells is suppressed. It was confirmed that the expression of CD300c of the present invention can be increased and the proliferation of cancer cells can be suppressed. The inhibitor or activity inhibitor is applicable to a variety of cancers and is useful for preventing and / or treating cancer. It is widely used in various cancer treatments because it can significantly increase the therapeutic effect. It is expected to be possible.
Claims
1. A pharmaceutical composition for preventing or treating cancer, comprising as an active ingredient a fusion protein comprising a soluble CD300c domain and an antibody constant region.
2. The pharmaceutical composition of claim 1, wherein the antibody constant region is Fc.
3. The pharmaceutical composition described in claim 1, wherein the soluble CD300c domain is an extracellular domain of CD300c protein.
4. The pharmaceutical composition described in claim 3, wherein the soluble CD300c domain consists of the amino acid sequence shown in sequence number 1.
5. The pharmaceutical composition of claim 1, wherein the fusion protein activates immune cells.
6. The pharmaceutical composition of claim 1, wherein the cancer is one or more selected from the group consisting of colorectal cancer, rectal cancer, colon cancer, thyroid cancer, oral cancer, pharyngeal cancer, laryngeal cancer, cervical cancer, brain cancer, lung cancer, ovarian cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, prostate cancer, skin cancer, tongue cancer, breast cancer, uterine cancer, gastric cancer, bone cancer and blood cancer.
7. The pharmaceutical composition of claim 1, further comprising another anticancer agent.
8. The pharmaceutical composition of claim 1, which inhibits cancer proliferation, survival, metastasis, recurrence or anticancer drug resistance.
Citation Information
Patent Citations
A method for modulating autophagy by modulating autophagy inhibitor gene products.
JP2013506686A
Compositions and methods for inhibition of lineage specific antigens
WO2017066760A1
Treatment of tumors by inhibition of CD300f
WO2018071576A1
